The study demonstrated that nivolumab showed good safety, providing a crucial foundation for the initiation of subsequent clinical trials evaluating anti-PD-1 antibody treatment for sepsis in large, international, and multicenter cohorts. This evidence concerns the gene PDCD1 and Sepsis.